Key Drivers
- Strong Cash Flow
- Rising Leverage
- Weaker Liquidity
AIAI Summary
GoodRx's upside depends on proving that its Family Plan can convert an episodic coupon business into higher-retention recurring household revenue, but with sales declining and ~$539 million of debt, investors should wait for measurable subscriber, utilization, and GAAP-profit improvement before underwriting a growth re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Leverage
- •Weaker Liquidity
GDRX delivers strong margins and cash flow, but deteriorating liquidity, elevated leverage, accumulated losses, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Support test
- •Resistance overhead
GDRX is mildly bearish over the last month; hold $3.34–$3.35 support and reclaim $3.56 to improve momentum, otherwise remain cautious.
Decline from the $3.65 peak reflects persistent selling pressure
Sentiment & News
Key News Insights:
- •Family Plan Launch
- •Broader Coverage
- •Employer Expansion
GoodRx launched a family plan covering up to four dependents and pets, with employer-benefit expansion planned for 2027.
The launch could strengthen GoodRx's recurring revenue and household customer reach
Similar Companies in Healthcare
Other companies in the same sector with AI ratings